

AMERICAN VIETNAMESE
BIOTECH INC

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No: 27/2026/AMV

Regarding information disclosure and explanations
Profit difference in the financial statements
The year 2025 has been audited.

Ho Chi Minh City, May 15, 2026

Dear: - STATE SECURITIES COMMISSION;
- HANOI STOCK EXCHANGE

Company Name: AMERICAN VIETNAMESE BIOTECH INC

Stock ticker: AMV

Head office address: 4th floor, Phu Ma Duong building, 85 Hoang Van Thai Street, Tan My Ward,
Ho Chi Minh City

Phone: Fax:

Information released by: Dang Nhi Nuong

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai Street, Tan My Ward, Ho Chi
Minh City

Telephone (mobile, office, home):

Type of information to be released: ☐ 24-hour ☐ irregular ☐ information as requested ☒
periodically

Content of published information (*):

In accordance with Circular No. 96/2020/TT-BTC dated November 16, 2020, of the Ministry of
Finance, Viet My Pharmaceutical and Medical Equipment Manufacturing and Trading Joint Stock
Company hereby reports to the Committee and the Department on the disclosure of the audited
financial statements for the fiscal year ending December 31, 2025, as follows:

I. Separate financial statements:

**1. Explanation of changes in pre-tax profit in the Income Statement for the reporting period
compared to the same period of the previous year:**

Target	2025 (VND)	2024 (VND)	Difference (VND)	Proportion
Revenue from sales and services	26,092,083,075	169,364,910,851	(143,272,827,776)	-84.59%
Cost of goods sold	23,253,299,467	160,394,730,660	(137,141,431,193)	-85.50%
Financial operating revenue	17,010,120,993	10,000,513,202	7,009,607,791	70.09%
Total accounting profit before tax	(42,910,980,816)	(12,651,723,096)	(30,259,257,720)	-239.17%

The Company's audited separate financial statements for 2025 decreased by 239.17% compared to
the same period of the previous year, equivalent to VND 30,259,257,720 . The main reason is the
decrease in sales revenue compared to the same period of 2024, leading to a decrease in profit in 2025
compared to 2024.



2. Explanation of the difference in pre- and post-audit profit

+ Profit before tax before audit: (24,475,611,371) VND

+ Profit before tax according to the audited financial statements: (42,910,980,816) VND

+ Profit before tax according to the audited financial statements decreased by VND 18,435,369,445 (a difference of 75.32%).

II. Consolidated financial statements

1. Explanation of changes in pre-tax profit in the Income Statement for the reporting period compared to the same period of the previous year:

Target	2025 (VND)	2024 (VND)	Difference (VND)	Proportion
Revenue from sales and services	159,996,502,630	310,354,603,848	(150,358,101,218)	-48.45%
Cost of goods sold	137,822,998,853	279,093,183,419	(141,270,184,566)	-50.62%
Financial operating revenue	3,001,841,868	1,899,672,917	1,102,168,951	58.02%
Total accounting profit before tax	(73,701,068,332)	(11,490,601,481)	(62,210,466,851)	-541.40%

consolidated financial statements for 2025 decreased by 541.40% compared to the previous year. The main reason is the decrease in sales revenue compared to the same period in 2024, leading to a decrease in profit in 2025 compared to 2024.

2. Explanation of the difference in pre- and post-audit profit

+ Profit after tax before audit: (54,503,718,617) VND

+ Net profit after tax according to the audited financial statements: (73,701,068,332) VND

+ Net profit after tax according to the audited financial statements decreased by VND 19,197,349,715 (a difference of 35.22%).

III. The above information was posted on our company's website on May 15, 2025 at the following address:

<https://amvibiotech.com/category/bao-cai-tai-chinh/>

American Vietnamese Biotech Inc commits that the information provided above is truthful and accurate.

Thank you very much!

Recipient:

- As above.
- Save VP.

AMERICAN VIETNAMESE BIOTECH INC

MANAGER



DANG NHI NUONG